Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk.
about
A validated model of serum anti-müllerian hormone from conception to menopauseSerum Müllerian inhibiting substance levels are lower in premenopausal women with breast precancer and cancer.Genetic variants in anti-Mullerian hormone and anti-Mullerian hormone receptor genes and breast cancer risk in Caucasians and African AmericansProspective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk.Serum antimüllerian hormone in healthy premenopausal women.Anti-Müllerian hormone concentrations in premenopausal women and breast cancer riskPlasma Anti-Müllerian Hormone Concentrations and Risk of Breast Cancer among Premenopausal Women in the Nurses' Health Studies.Early Life Body Fatness, Serum Anti-Müllerian Hormone, and Breast Density in Young Adult Women.Müllerian inhibiting substance/anti-Müllerian hormone: a potential therapeutic agent for human ovarian and other cancers.Antimüllerian hormone in relation to tobacco and marijuana use and sources of indoor heating/cooking.Potential therapeutic applications of human anti-Müllerian hormone (AMH) analogues in reproductive medicine.Anti-Mullerian hormone and endometrial cancer: a multi-cohort study.Demographic, lifestyle, and other factors in relation to antimüllerian hormone levels in mostly late premenopausal women.Anti-Müllerian hormone and risk of ovarian cancer in nine cohorts.Circulating anti-Müllerian hormone and breast cancer risk: A study in ten prospective cohorts.Circulating Hormones and Mammographic Density in Premenopausal Women.
P2860
Q21135308-266FD463-E39A-4B1E-95A6-8068447B41C6Q33912912-91DE8D40-80C3-4E64-8E79-4C947F474B26Q34426520-C9B0E6C3-5033-43F5-B375-B5BEB00C3292Q34613562-6B7060F2-5F86-430D-8DD4-296CD2F479D7Q35185385-B42CFAA5-A0C0-4725-A628-2E235EF0F8A8Q35675000-68ABFD11-A97B-4BD0-98BB-6E9AB93C1966Q36917692-90837BBF-EA58-4B13-B6D1-5A38B4AA1BDBQ37059875-ECDCC1FD-06C7-4605-B345-0C0151F1DC12Q37707380-DB7793AE-DDA9-4A5F-8D21-E2495262A2EFQ38380074-81128F0E-D614-432B-B115-92D0B65DDBBAQ39393122-2A5B39E0-ABF9-4DA6-8135-3EFE78281DEBQ40057472-673AB1AF-AAE2-4905-A36F-63B6193ACF85Q40263318-8721F33B-926E-4984-8BA2-690E2996227DQ47969294-C1EC87EA-9293-4C26-9ED8-C70A6CC92038Q48283361-6E3210CF-8CEA-4A09-88FC-FCBEA716E33DQ50057758-D8F3AC78-586D-42BC-859C-AB27F1CD9EB7
P2860
Prospective case-control study of serum mullerian inhibiting substance and breast cancer risk.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 09 October 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Prospective case-control study ...... stance and breast cancer risk.
@en
Prospective case-control study ...... stance and breast cancer risk.
@nl
type
label
Prospective case-control study ...... stance and breast cancer risk.
@en
Prospective case-control study ...... stance and breast cancer risk.
@nl
prefLabel
Prospective case-control study ...... stance and breast cancer risk.
@en
Prospective case-control study ...... stance and breast cancer risk.
@nl
P2093
P2860
P356
P1476
Prospective case-control study ...... stance and breast cancer risk.
@en
P2093
Andrew K Godwin
Brian L Egleston
Christiana M Shaw
Cynthia S Spittle
Frank Z Stanczyk
Joanne F Dorgan
Lisa L Kahle
P2860
P304
P356
10.1093/JNCI/DJP331
P407
P577
2009-10-09T00:00:00Z